natgillin/translations-raw huggingface dataset:
The method of claim 13, wherein the disease is modulated by wild type or mutant CSF1R, FLT3, KIT, and/or PDGFRB kinase. 
Tvar za uporabu u skladu s patentnim zahtjevom 20, pri čemu je bolest modulirana divljim tipom ili mutiranim CSFIR, FLT3, KIT i/ili PDGFRB kinazom.
A bispecific antibody according to any one of embodiment 1 to 21, characterized in that in addition to the amino acid replacement at position 124 in the constant domain CL the amino acid at position 123 is substituted independently by lysine (K), arginine (R) or histidine (H). 
Bispecifično antitijelo prema bilo kojem od zahtjeva 1 do 4, naznačeno time, što je pored zamjene amino-kiseline na poziciji 124 u stalnoj domeni CL amino-kiselina na poziciji 123 supstituirana nezavisno lizinom (K), argininom (R) ili histidinom (H).
Example: A dispersion of zirconia in a resin base can be light cured. 
Primjer: Disperzija cirkonijeva oksida u bazi za smolu može lako očvrsnuti.
is provided with a catch, or catching means, located closer to the proximal end than to the distal end of the latch, wherein said catching means may comprise either an opening in the latch, or a lug extending transverse to the latch. such that the pivoting of anyone of the at least first and second latches about its respective hinge from its respective idle position to its respective fixing position reduces the distance separating the catching means thereof from the centroid of the central opening. 
- opremljen je sredstvima za zahvaćanje (33, 33a) koja se nalaze bliže proksimalnom kraju nego distalnom kraju zasuna, tako da se okretanje bilo kojeg od prvih i drugih zasuna (32) oko odgovarajućeg zgloba (36) iz odgovarajućeg položaja praznog hoda u odgovarajući položaj za pričvršćenje smanjuje udaljenost koja razdvaja sredstva za zahvaćanje (33, 33a) od središta središnjeg otvora.
A composition for use according to claim 3, wherein the patient has a rate of urine production during sleep that is greater than the patient's overall average daily rate of urine production. 
Pripravak za uporabu prema zahtjevu 8, naznačen time da pacijent ima stopu proizvodnje urina tijekom spavanja veću od stope cjelodnevne proizvodnje urina pacijenta; i/ili pri čemu je pacijent stariji od 65 godina s razinom natrija u serumu, nakon administracije, od barem 135.
a method of inhibiting a cancer stem cell to treat cancer in a subject, the method comprising administering to the subject a therapeutically effective amount of the pharmaceutical composition. The compound or pharmaceutical composition for use of claim 1, parts (ii) to (vii) wherein the cancer: is selected from the group consisting of breast cancer, head and neck cancer, lung cancer, ovarian cancer, pancreatic cancer, colorectal carcinoma, prostate cancer, renal cell carcinoma, melanoma, hepatocellular carcinoma, cervical cancer, sarcomas, brain tumors, gastric cancers, gastrointestinal cancer, esophageal cancer, bladder cancer, multiple myeloma, leukemia, and lymphomas; and/or 
Spoj prema zahtjevu 12 gdje je u slučaju (1) spoj za liječenje poremećaja povezanog s neprirodnom aktivnošću signalnog puta Stat3 u subjekta i gdje se neprirodna aktivnost signalnog puta Stat3 može odrediti ekspresijom fosforiliranog Stat3 ili surogatom uzvodnog ili nizvodnog regulatora Stat3 fosforilacije i gdje je poremećaj (i) rak izabran iz skupine koju čine rak dojke, rak glave i vrata, rak pluća, rak jajnika, rak gušterače, kolorektalni karcinom, rak prostate, karcinom renalnih stanica, melanom, hepatocelularni karcinomi, rak cerviksa, sarkomi, tumori mozga, rakovi želuca, multipli mijelom, leukemija, limfomi;
shea butter in an amount of from about 15% to about 35% by weight of the total composition 
shea maslac u količini od 15% do 35 masenih% ukupnog pripravka
The topical cosmetic formulation of claim 1, wherein the first defensin is encapsulated in a liposome. 
Topikalna kozmetička formulacija u skladu s patentnim zahtjevom 1, naznačena time što je prvi defenzin inkapsuliran u liposom.
220-300 mg of concentrated r-hlL-18BP obtained from capture step reported above under (1) were thawed and adjusted to pH to 8.5 ± 0.1, conductivity 50±5 mS/cm by adding few drops of 35% ortho-phosphoric acid (H3PO4) and solid NaCl in the amount corresponding to about 0.35M. 
HR P20070196 T3 220-300 mg koncentriranog r-hIL-18BP koji je dobiven u koraku lovljenja opisan ranije (1) bilo je otopljen i bio mu je podešen pH na 8.5 + 0.1, provodljivost na 50+5 mS/cm dodavanjem nekoliko kapi 35% orto-fosforne kiseline (H3POx) i krutog NaCI u količini koja odgovara 0.35 M.
provided that the halogens on the halogen substituted C1-4alkyl or the halogen substituted C1-4alkoxy are selected from the group consisting of chloro and fluoro; 
uz uvjet da se halogeni elementi u halogenom supstituiranim C1-4alkilnim i C1-4alkoksi skupinama odabiru iz skupine koju sačinjavaju kloro i fluoro;
adding the aliquot of protein carrier required over a period of 1 minute to 6 hours, wherein at least one quarter of the aliquot is added over the first half of the period, and at least one quarter of the aliquot over the second half of the period; 
dodavanja alikvota proteinskog nosača potrebnog u periodu od 5 minuta do 6 sata, gdje se najmanje jednu četvrtinu alikvota dodaje tijekom prve polovine perioda, a najmanje jednu četvrtinu alikvota tijekom druge polovine perioda;
A kit comprising at least one binding molecule according to any one of claims 1-3, an immunoconjugate according to claim 4, or a pharmaceutical composition according to any one of claims 10-12, or a combination thereof. 
Pribor, naznačen time, da sadrži najmanje jednu molekulu za vezanje u skladu s bilo kojim od patentnih zahtjeva 1-3, imunokonjugat u skladu s patentnim zahtjevom 4 ili farmaceutski pripravak u skladu s bilo kojim od patentnih zahtjeva 10 - 12 ili njihovu kombinaciju. t>&
converting Compound 10 to Compound 6. The process of claim 48, wherein said acid is glyoxylic acid. 
Postupak u skladu s patentnim zahtjevom 48, naznačen time što navedena kiselina je glioksilna kiselina.
Thus it can be noted that with nine passes (but even with a lower number of passes) and a reduced amount of the demanded power from a bloom with a side size of 250 mm, a round bar with a diameter of 70 mm of excellent quality can be obtained. A process for manufacturing steel long products, such as bars, wire, angle irons, beams and rails, from a continuous casting step of blooms/billets having thickness comprised between 120 and 400 mm and "mass flow", i.e. the quantity of steel flowing in the time unit at the outlet of continuous casting >3m/min, this step including a liquid core reduction and followed by an induction heating step, without interruptions until the end of a rolling step in a plurality of stands, characterized by the fact that when entering the rolling step the average temperature of the product is higher than the surface temperature and the difference between the temperature in the core or middle inner region and the surface temperature, which is of about 1200°C, is of at least 100°C. 
Proces proizvodnje čeličnih proizvoda velike dužine, kao što su čelične šipke, žice, kutni čelični komadi, grede i šine, postupkom koji sadrži korak kontinualnog izlijevanja poluproizvoda izlazne debljine 120-400 mm i "protoka mase" tj. količine čelika koja u jedinici vremena istječe iz procesa kontinualnog lijevanja, koji je > 3 m/min, pri čemu spomenuti korak proizvodnog procesa sadrži i korak smanjenja osne (centralne) likvacije, praćen korakom indukcijskog zagrijavanja i završnim korakom obrade valjanjem u nizu valjačkih stanova, pri čemu je cijeli postupak, koji se odvija kontinualno i bez prekida, naznačen time što je srednja temperatura poluproizvoda na ulazu u valjaonicu viša od temperature na površini spomenutog poluproizvoda, dok razlika temperatura u jezgri i na površini poluproizvoda (gdje se temperatura kreće oko 1200%C), iznosi najmanje 100*C.
The active ingredients may be administered from 1 to 6 times a day, sufficient to exhibit the desired activity. 
Djelatni sastojci mogu se davati od 1 do 6 puta na dan, u dovoljnoj količini za postizanje poželjnog djelovanja.
The compound of claim 1, having a weight/weight chloride content between 13.5 and 14.5% and an ethanol content of at least 0.5 mol/mol. 
Spoj prema zahtjevu 1, naznačen time, da je on solvat i da ima sadržaj organskog otapala ili sadržaj vode od najmanje 0,5 mol/mol.
Generally the applied composition will contain sufficient active principle to be diffused into the nail so that the application should be repeated only once or twice per day in order to ensure its effectiveness. 
Obično će primjenjeni pripravak sadržavati dovoljno aktivnog sastojka koji će difundirati u nokat, tako da se pripravak mora nanijeti samo jedanput ili dvaput dnevno kako bi se osigurala učinkovitost. HR P20070431 T3
ii) a light chain comprising SEQ ID NO:14. 
varijabilna laku domenu koja sadrži SEQ ID NO: 165.
Pharmaceutical composition according to claim 2 in form of a tablet, capsule, powder, pellet, suspension, emulsion, cream, gel, ointment, lotion, dispersion or paste. 
Farmaceutski pripravak u skladu s patentnim zahtjevom 19, naznačen time što je navedeni pripravak u obliku tablete, kapsule, praška, peleta, suspenzije, emulzije, kreme, gela, masti ili paste.
A combination for use according to claim 3 wherein the combination is administered simultaneously. 
Kombinacija za upotrebu u skladu s patentnim zahtjevom 3, naznačena time što se kombinaciju primijenjuje istodobno.
Two-component polyurethane adhesives are applied from two different ingredients, and also cure by means of the wood humidity. 
Dvo-komponenina poliuretanska ljepila su sastavljena od dvije različite komponente, i također se obavlja lijepljenje uz pomoć vlage iz drva,
The method according to claim 1 wherein the water soluble polymer is PEG. The method according to claim 1 wherein the oxidized carbohydrate moiety of FVIII is located in the activation peptide of FVIII. 
Postupak prema zahtjevu 2, pri čemu kada je terapeutski protein protein zgrušnjavanja krvi, oksidirani dio karbohidrata terapeutskog proteina je lociran u aktivacijskom peptidu spomenutog proteina zgušnjavanja krvi.
Method of fuel for energetics production according to claims 1 and 2 characterized by that the heated up spaces of heated units (2,3) are maintained continually in heated up state and the charge is put into at least two pressure vessels (1) and these are heated stepwise, so that after removal of one pressure vessel (1), another pressure vessel (1) is placed to its place. 
Način proizvodnje goriva za energetiku na temelju zahtjeva 1 i 2, naznačen time što zagrivani prostori zagrijavanih jedinica (2,3) se održavaju kontinualno u zagrivanom stanju i zasip se ubacuje barem u dvije tlačne posude (1) 1 iste se zagrivaju postupno tako da se nakon uklanjanja jedne tlačne posude (1) na njezino mjesto smješta sledeća tlačna posuda (1).
Examples of suitable bases include: sodium hydroxide, potassium carbonate, triethylamine, alkali metal hydrides, such as sodium hydride and potassium hydride; alkyllithium compounds, such as methyllithium and butyllithium; and alkali metal alkoxides, such as sodium methoxide and sodium ethoxide. 
Primjeri pogodnih baza uključuju: natrijev hidroksid, kalijev karbonat, trietilamin, hidride alkalnih metala, poput natrijevog hidrida i kalijevog hidrida; alkillitijeve spojeve, poput metillitija 1 butillitija; te alkokside alkalnih metala, poput natrijevog metoksida i natrijevog etoksida.
The method of claim 1, wherein the first nucleic acid, the second nucleic acid, or both nucleic acids are at least 10 kb. 
prva nukleinska kiselina, druga nukleinska kiselina, ili obje nukleinske kiseline uključuju bakterijski umjetni kromosom; i/ili
Use of HuLuc63 in the preparation of a first medicament, said HuLuc63 being a humanized IgG1 antibody having a heavy chain variable region corresponding to SEQ ID NO:5 and a light chain variable region corresponding to SEQ ID NO:6, and the use of lenalidomide in the preparation of a second medicament, said medicaments for use in the treatment of multiple myeloma, wherein the first medicament is administered concurrently, prior to or following the administration of the second medicament. 
Upotreba HuLuc63 u pripravi lijeka, spomenuti HuLuc63 kao humanizirano antitijelo IgG1 ima varijabilno područje teškog lanca koje odgovara sekvenci SEQ ID NO:5 i varijabilno područje lakog lanca koje odgovara sekvenci SEQ ID NO:6; za liječenje multiplog mijeloma ljudskog pacijenta, gdje se HuLuc63 primijenjuje u kombinaciji s bortezomibom i gdje se HuLuc63 daje kao intravenozna infuzija u dozi od 2.5 mg/kg do20 mg/kg, a bortezomib se treba primijeniti kao intravenozna infuzija u dozi od 0.2 mg/m2 do 2.0 mg/m2.
The qualitative and quantitative detection of the protein Serum amyloid P-component (SAP, SAMP, SwissProt No: P02473) in a biological fluid from a pregnant woman and 
Kvantitativnu detekciju proteinskog seruma amiloidne komponente P (SAP, SAMP, SwissProt br. P02743) u perifernoj krvi, serumu i/ili plazmi od trudne žene, i
Ar is selected from the group consisting of phenyl and thiophen-yl; is selected from the group consisting of unsubstituted imidazolyl and substituted imidazolyl, wherein the substituted imidazolyl group is substituted with C1-C6 alkyl; 
je odabran iz skupine koju čine: vodik, C1-C6 alkil, C3-C6cikloalkii, aril, supstituirani aril, heteroaril i supstituirani heteroaril, gdje su aril, heteroaril i supstituenti za aril i heteroaril prethodno definirani;
a reference pixel filtering unit configured to adaptively filter reference pixels of a current luma block based on the luma intra prediction mode and the size of the luma transform unit; 
jedinicu (350) za filtriranje referentnih piksela konfiguriranu da adaptivno filtrira referentne piksele tekućeg luma bloka na osnovi luma intrapredikcijskog režima i veličine luma transformacijske jedinice i da ne filtrira referentne piksele tekućeg kroma bloka;
/ 560 absorption ratio 
A280/560 apsorpcijski omjer
The designing process is a relief (4) formed by means of embossing on the inward facing surface of the filling layer (2). Relief (4) is the painting layer forming thickness and colour. Figure 2 shows a process according to the invention. 
Postupak kreiranja trodimenzionalne slike unutar transparentnog kamena (1) prema bilo kojem od predhodnih zahtjeva, naznačen time da navedeni drugi postupak dizajniranja je najmanje reljef (4) formiran na unutarnjoj površini navedenog sloja punjenja utiskivanjem.
The pharmaceutical aerosol formulation of any one of the claims 1 to 4 for use for the prevention and/or treatment of mild, moderate or severe, acute or chronic symptoms or for prophylactic treatment of a respiratory disease. 
Farmaceutska aerosolna formulacija iz bilo kojeg od patentnih zahtjeva 1 do 4, naznačena time da je za prevenciju i/ili liječenje blagih, umjerenih ili ozbiljnih akutnih ili kroničnih simptoma ili za profilaktičko liječenje respiratornih bolesti.
at least one stabilizer cetostearyl alcohol or glyceryl stearate or a mixture thereof, 
mješavinu cetostearil alkohola i gliceril stearata kao stabilizator,
A compound represented by the general formula (1): 
Spoj predstavljen općom formulom (1):
The benzoylpyrazole compound or its salt according to Claim 2, wherein R1 is methyl R2 is a hydrogen atom, R3 is ethyl, R4 is methyl, R5 is 2-methoxyethoxy, R6 is methylsulfonyl, and A is represented by the formula (a-1): 
Spoj benzoilpirazola ili njegove soli u skladu s patentnim zahtjevom 2, naznačen time, da je R! metil, R? je atom vodika, Rž je etil, R* je metil, R? je 2-metoksietoksi, R" je metilsulfonil a A je predstavljen formulom (a-1):
said undercut portion of said longitudinal profile groove, at its innermost part inside said ridge portion (128), is expanded into a longitudinal pocket (135) having opposite lateral wall portions (132,133) and a lowermost transverse end wall (134), which is substantially flat or slightly curved; 
navedeni podrezani dio navedenog uzdužnog profila utora, na njegovom krajnjem unutarnjem dijelu unutar navedenog dijela grebena (128), je proširen u uzdužni džep (135) koji ima suprotne bočne dijelove stjenke (132,133) 1 najdonju poprečnu krajnju stjenku (134), koja je uglavnom plosnata ili blago zakrivljena;
The column was then rinsed with at least 6 BV of purified water. 
Kolona se tada opere s najmanje 6 BV pročišćene vode.
feeding the micronisation chamber of a wet milling apparatus, optionally containing grinding media, with a water immiscible anti-solvent which is liquid at room temperature and pressure, also having a dielectric constant lower than 15 and a density of 1.3 to 2 g/cm3; 
dodavanje u komoru za mikronizaciju aparata za mokro mljevenje koji sadrži medij za mljevenje, s anti-otapalom koje se ne miješa s vodom odabrano iz skupine koju čine perfluorodekan, dekafluoropentan i 2H,3H-dekafluoropentan;
Composite according to claim 1, characterised in that titanium dioxide is prevalently in the anatase crystallographic form. 
Uporaba prema zahtjevima 1 do 4, naznačena time što je u tom kompozitu titanijev dioksid većinom u kristalografskom obliku anataze.
An isolated cell comprising the vector of claim 8 . A composition comprising an immunogenically effective amount of the vector of claim 8, and a carrier. 
Pripravak naznačen time što sadrži imunogeno učinkovitu količinu vektora prema bilo kojem od patentnih zahtjeva 8-10, i nosač.
The Janus kinase inhibitor as claimed in claim 29, wherein the Janus kinase is Janus kinase 3. 
Inhibitor Janus kinaze u skladu s patentnim zahtjevom 29, naznačen time što je Janus kinaza Janus kinaza 3.
Acomposition accordingto claim 1 comprising 9% to 13% (wt/wt) magnesium and 8% to 12% (wt/wt) potassium on a dry basis, having a bulk density of 0.55 to 0.65 g/cm3. 
Sastav usklađen s patentnim zahtjevom 1 obuhvaća 9% do 13 % (wt/'wt) magnezija 1 8% do 12% (wt/wt) kalija u suhoj osnovi, ima ukupnu gustoću od 0,55 do 0,65 g/cm3.
and R2, when attached to the same carbon atom, can combine to form cycloalkyl or monocyclic saturated heterocyclyl togive a spiro ring wherein the cycloalkyl or monocyclic saturated heterocyclyl can be optionally substituted with Rd, Re, or Rf independently selected from alkyl, alkoxy, fluoro, fluoroalkyl, fluoroalkoxy, hydroxy, monosubstituted amino, or disubstituted amino; or R1 and R2, when attached to carbon atoms 2 and 5 or 3 and 6 positions of the piperazine ring, can combine to form -C1-C3- alkylene chain wherein one of the carbon atoms in the alkylene chain is optionally replaced by a -NR-, -O-, -S(O)n1- (where R is hydrogen or alkyl and n1 is 0-2) and further wherein one or two hydrogen atoms in the alkylene chain can be optionally substituted with one or two alkyl; 
i R2 kada su vezani na isti atom ugljika, se mogu kombinirati i tvoriti cikloalkil ili monociklički zasićeni heterociklil da se dobije spiro prsten pri čemu cikloalkil ili monociklički zasićeni heterociklil može biti proizvoljno supstituiran sa Rd, Re, ili Rf neovisno odabranim od alkila, alkoksi, fluoro, fluoroalkila, fluoroalkoksi, hidroksi, monosupstituiranog amino ili disupstituiranog amino; ili
The method of claim 1, wherein the vaccine comprises diphtheria toxoid adsorbed onto aluminium hydroxide, or aluminium phosphate, or a mixture of both, wherein adsorption takes place either before or after mixing with other antigens. 
Postupak u skladu s patentnim zahijevom 11, naznačen time što je navedeni konjugat adsorbiran na aluminijev fosfat ili neadsorbiran na adjuvans, te što se adsorciju provodi bilo prije ili nakon miješanja s drugim antigenima.
An AAV capsid protein having an amino acid sequence which has at least 99% identity to the sequence of SEQ ID NO: 3. 
ima identitet najmanje 99 %-tno jednak sekvenci SEQ ID NO: 3 i jeste hibridni kapsid koji sadrži regije kapsida AAV3B i AAV8.
Spy0416, wherein the Spy0416 protein antigen has an amino acid sequence that is at least 90% identical to SEQ ID NO:1. 
(3) Spy0416, gdje proteinski antigen iz SpyO0416 ima aminokiselinski slijed koji je najmanje 90% istovjetan s SEQ ID NO:1.
the heavy chain comprises an amino acid sequence represented by SEQ ID NO: 120 and the light chain comprises an amino acid sequence represented by SEQ ID NO: 129; 
sekvence nukleinske kiseline koja kodira polipeptid koji sadrži varijabilno područje teškog lanca koje sadrži aminokiselinsku sekvencu od SEQ ID NO: 133 i varijabilno područje lakog lanca koje sadrži aminokiselinsku sekvencu od SEQ ID NO: 138; i
The method according to any one of claim 1 to 17 and 19 to 22, characterized in that cultivation is performed at a volume of at least 100 1, more preferably of at least 500 1, most preferably of at least 1000 1. 
Postupak prema bilo kojem od patentnih zahtjeva 1 do 17 1 19 do 22, naznačen time, da se kultivacija izvodi pri volumenu od najmanje 100 1, poželjnije najmanje 500 1, najpoželjnije najmanje 1000 1.
oilseed rape, canola (brassica napus)), without damaging these crops. 
uljane repice, kanole (Brassica napus)), bez oštećenja ovih kultura.
a VH having the sequence represented by SEQ ID NO: 20; and a VL having the sequence represented by SEQ ID NO: 26. 
VH koji ima sekvencu predstavljenu sa SEQ ID NO: 20; i VL koji ima sekvencu predstavljenu sa SEQ ID NO: 26.
Use of a compound according to claim 11 or 12, wherein R3 and R5 are independently selected from the group consisting of hydrogen, halogen, C1-6-alkyl, preferably methyl, C1-6-alkoxy, preferably methoxy, C1-6-alkoxy-C1-6-alkoxy, preferably 2-methoxy-ethoxy, trifluoromethyl and trifluoromethoxy. 
Upotreba spoja, koji je dan patentnim zahtjevom 11 ili 12, naznačena time, da R* i R* su neovisno odabrani iz skupine koja vodik, halogen, C;-alkil, preferirano metil, Ci.g-alkoksi, preferirano metoksi, C;.g-alkoksi-C;.4- alkoksi, preferirano 2-metoksi-etoksi, trifluorometil i trifluorometoksi.
used for manufacture of a medication for treatment of diseases associated with CFTR protein malfunction, or its tautomers, E and Z geometric isomers, enantiomers, diastereomers, or pharmaceutically acceptable salts thereof or complexes thereof. 
[image] njeni tautomeri, E i Z geometrijski izomeri, optički aktivni oblici kao što su enantiomeri, dijastereoizomeri i njihovi racematni oblici ili smjese stereoizomernih oblika ili njihovih farmaceutski prihvatljivih soli ili kompleksa; pri čemu je Z1 nezavisno odabran iz grupe koja se sastoji od:
The method according to claim 13 wherein the disease or condition is prostate cancer. 
Spoj za uporabu prema patentnom zahtjevu 15 naznačen time što bolest ili stanje je rak prostate.
The present invention accordingly provides a process for the mineralization of carbon dioxide to form a magnesium carbonate compound, which process comprises contacting the carbon dioxide, in the free form or in the form of an alkali metal bicarbonate or carbonate, with an alkali metal magnesium silicate to produce the magnesium carbonate compound. 
Postupak za mineralizaciju ugljikovog dioksida kako bi se formirao spoj magnezij karbonata, postupak sadrži dovođenje u kontakt ugljikovog dioksida, u slobodnom obliku ili u obliku bikarbonata ili karbonata alkalnog metala, sa magnezij silikatom alkalnog metala kako bi se proizveo spoj magnezij karbonata.
MC-S-P wherein: at least one (radio)metal (M) and a chelator (C) which stably binds M; alternatively MC may represent a Tyr- or a prosthetic group carrying a (radio)halogen; 
M je radiometal i C je metalni kelator koji stabilno veže M ili MC je Tyr- ili prostetska skupina vezana na radiohalogen, pri čemu je M radiohalogen;
The FGF-18 compound for use according to claim 1, wherein said administrations are separated by about 3 weeks or by about 4 weeks. 
Spoj FGF-18 za uporabu prema zahtjevu 1, naznačen time što navedena davanja su odvojena 2 tjedna.
The pharmaceutical composition claim 7, wherein said at least 80% of said placental stem cells express OCT-4. The pharmaceutical composition of claim 1, wherein at least 90% of said placental stem cells express CD73, CD105, and CD200. 
Izdvojena populacija matičnih stanica iz posteljice u skladu s patentnim zahtjevom 14, naznačena time što navedenih najmanje 80% od navedenih matičnih stanica iz posteljice eksprimira CD73, CD105 i CD200.